CRO Health Decisions Names Industry Veteran Stephen DeCherney, MD, MPH, Interim CEO

Durham, North Carolina. Health Decisions, Inc., the full-service clinical research organization of choice for forward-looking biopharma and medical device companies, today announced the appointment of G. Stephen DeCherney, MD, MPH, as Interim CEO, effective immediately.

Dr. DeCherney was formerly a senior executive at Quintiles Global Transnational and PRA International. He has managed clinical research staff in 53 countries and has converted systems for Statistical Process Control in manufacturing for use in management of service businesses. Dr. DeCherney is Clinical Professor of Medicine at the University of North Carolina at Chapel Hill in the Division of Endocrinology, Adjunct Professor at UNC's Kenan-Flagler Business School and a director of several corporations active in drug development and clinical research.

"I look forward to working with the Health Decisions Executive Team to ensure continuity in management at all levels," said Dr. DeCherney. "Our first priorities are to continue providing high-quality, high-efficiency services to sponsors of Health Decisions' ongoing clinical trials and to bring additional projects in the pipeline to fruition."

"We are fortunate to have Steve DeCherney heading the leadership team at Health Decisions following the tragic death of our former CEO and founder, Michael Rosenberg last week," said Health Decisions' Executive Vice President and Director of Biometrics James Higgins, PhD. "Our executive team knows Steve very well and I know that he will keep Health Decisions on a successful path consistent with our company DNA, which is innovation that provides high efficiency while maintaining high quality in clinical development services. Steve is not only a fine clinical research professional and executive, but also an innovator in his own right."

In addition, Dr. Higgins noted that Dr. DeCherney's background and perspective on clinical development projects are completely aligned with that of Michael Rosenberg. "They both held Master's degrees in public health as well as doctorates in medicine," Dr. Higgins said. "They were friends and they often discussed issues and trends in clinical development."

Dr. Higgins stated that Dr. DeCherney will play an active role in Health Decisions' search for a new CEO. Dr. DeCherney will serve as Interim CEO until a new CEO is named.

Dr. DeCherney holds an MD from Temple University and an MPH and BA from Columbia University.

About Health Decisions

Health Decisions is the CRO of choice for forward-looking biopharma and medical device companies and a driving force in the modernization of clinical development. Health Decisions uses data-driven insight and agility to deliver clinical development success, reduce timelines and risk and increase quality and returns for biopharma and medical device companies worldwide. For 25 years and in more than 300 clinical trials involving tens of thousands of patients in many therapeutic areas, Health Decisions has improved the efficiency of clinical development through innovative methodology, processes and technology as reflected in Health Decisions' winning awards including the 2013 CIO 100 Award and 2014 Association of Clinical Research Professionals Innovation in Clinical Research Award. Health Decisions' clinical-development services consistently enable biopharma and device companies to bring new products to market faster and at lower cost, thus providing the public with earlier access to improved treatments and diagnostics at more affordable prices. Health Decisions is headquartered in Durham, NC and operates on five continents.

# # #

Media Inquiries
Health Decisions
Leslie Hammill
Marketing Specialist
+1 919.967.1111 ext. 520
lhammill @ healthdec.com

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.